Your StoryThe Free News and Press Release Resource.

DUBLIN–(BUSINESS WIRE)– Research and Markets(http://www.researchandmarkets.com/research/cfaf68/stakeholder_insigh) has announced the addition of the “Stakeholder Insight: Non-Hodgkin’s Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)” report to their offering.

The treatment outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients have improved since the introduction of Rituxan/MabThera (rituximab; Biogen Idec/Genentech/Roche/Chugai/Zenyaku Kogyo). However, an unmet need remains for novel agents with improved efficacy and toxicity profiles, particularly in the treatment of relapsed and refractory patients.

Scope

Highlights of this title

Treatment of DLBCL patients with Rituxan has increased cure rates. However, relapsed/refractory patients who are ineligible for stem cell transplant and patients who relapse following transplantation continue to have a poor prognosis. The drugs currently in late Phase development for DLBCL are expected to have minimal impact on patient prognosis.

Current treatment options in advanced FL are rarely curative but Rituxan has been shown to improve prognosis. Patients with advanced disease inevitably relapse and require further treatment. A need remains for novel therapies in the treatment of relapsed/refractory FL to improve survival rates in this hard-to-treat patient population.

The combination of Treanda (bendamustine) with Rituxan has a favorable toxicity profile and has been shown to be effective in the treatment of low-grade NHL. Recent promising clinical trial results suggest that this drug combination has the potential to become a standard of care in the treatment of patients with FL.

Key reasons to purchase this title

Key Topics Covered:

For more information visit http://www.researchandmarkets.com/research/cfaf68/stakeholder_insigh

Source: Datamonitor